Phase 3
N=581
Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines
Neisseria Meningitidis · Haemophilus Influenzae Type b
Bottom Line
View on ClinicalTrials.gov: NCT00891176 ↗Enrolled (actual)
581
Serious AEs
0.0%
Results posted
Dec 2010
Primary outcome: Primary: Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Titers Using Rabbit Complement (rSBA-MenC) Equal to or Above Cut-off Value — 120; 144; 127; 113 subjects
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- MenitorixTM (Biological); Pneumococcal conjugate vaccine GSK1024850A (Biological); PrevenarTM (Biological); MeningitecTM (Biological); NeisVac-CTM (Biological); InfanrixTM hexa (Biological); InfanrixTM penta (Biological); InfanrixTM IPV/Hib (Biological); InfanrixTM IPV (Biological)
- Age
- Pediatric · 0+ yrs
- Sex
- All
- Sponsor
- GlaxoSmithKline
- Primary completion
- Nov 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Titers Using Rabbit Complement (rSBA-MenC) Equal to or Above Cut-off Value |
97; 132; 108; 98 | — |
| PRIMARY Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Titers Using Rabbit Complement (rSBA-MenC) Equal to or Above Cut-off Value |
97; 132; 108; 98 | — |
| PRIMARY Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Titers Using Rabbit Complement (rSBA-MenC) Equal to or Above Cut-off Value |
97; 132; 108; 98 | — |
| SECONDARY Number of Subjects With an rSBA-MenC Titer Equal to or Above Cut-off Value |
49; 79; 75; 58 | — |
| SECONDARY rSBA-MenC Titers |
7.2; 11.9; 10.1; 8.5 | — |
| SECONDARY Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentrations Equal to or Above Cut-off Values |
126; 132; 130; 132; 85; 77 | — |
| SECONDARY Anti-PRP Concentrations |
1.655; 1.647; 2.947; 2.558 | — |
| SECONDARY Antibody Concentrations Against Vaccine Pneumococcal Serotypes |
0.19; 0.22; 0.20; 0.11; 0.14; 0.14 | — |
| SECONDARY Number of Subjects With Opsonophagocytic Activity |
33; 32; 20; 12; 49; 50 | — |
| SECONDARY Concentration of Antibodies Against Protein D |
284.7; 278.0; 266.1; 105.2 | — |
| SECONDARY Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Equal to or Above Cut-off Values |
110; 121; 110; 113; 110; 113 | — |
| SECONDARY Anti-HBs Antibody Concentrations |
211.1; 189.2; 154.5; 218.9; 130.8; 128.4 | — |
| SECONDARY Number of Subjects With Serious Adverse Events (SAEs) |
0; 0; 0; 0; 0; 0 | — |
| SECONDARY rSBA-MenC Titers |
7.2; 11.9; 10.1; 8.5 | — |
| SECONDARY Number of Subjects With an rSBA-MenC Titer Equal to or Above Cut-off Value |
49; 79; 75; 58 | — |
| SECONDARY Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentrations Equal to or Above Cut-off Values |
126; 132; 130; 132; 85; 77 | — |
| SECONDARY Anti-PRP Concentrations |
1.655; 1.647; 2.947; 2.558 | — |
| SECONDARY Antibody Concentrations Against Vaccine Pneumococcal Serotypes |
0.19; 0.22; 0.20; 0.11; 0.14; 0.14 | — |
| SECONDARY Number of Subjects With Opsonophagocytic Activity |
33; 32; 20; 12; 49; 50 | — |
| SECONDARY Concentration of Antibodies Against Protein D |
284.7; 278.0; 266.1; 105.2 | — |
| SECONDARY Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Equal to or Above Cut-off Values |
110; 121; 110; 113; 110; 113 | — |
| SECONDARY Anti-HBs Antibody Concentrations |
211.1; 189.2; 154.5; 218.9; 130.8; 128.4 | — |
| SECONDARY Number of Subjects With Serious Adverse Events (SAEs) |
0; 0; 0; 0; 0; 0 | — |
| SECONDARY Number of Subjects With rSBA-MenC Titer Equal to or Above Cut-off Value |
11; 19; 15; 14 | — |
| SECONDARY rSBA-MenC Titers |
7.2; 11.9; 10.1; 8.5 | — |
| SECONDARY Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentrations Equal to or Above Cut-off Values |
126; 132; 130; 132; 85; 77 | — |
| SECONDARY Anti-PRP Concentrations |
1.655; 1.647; 2.947; 2.558 | — |
| SECONDARY Antibody Concentrations Against Vaccine Pneumococcal Serotypes |
0.19; 0.22; 0.20; 0.11; 0.14; 0.14 | — |
| SECONDARY Concentration of Antibodies Against Protein D |
284.7; 278.0; 266.1; 105.2 | — |
| SECONDARY Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Equal to or Above Cut-off Values as Measured by ELISA. |
92; 92; 91; 87; 78; 86 | — |
| SECONDARY Anti-HBs Antibody Concentrations as Measured by ELISA |
433.8; 332.3; 302.7; 396.5; 270.5; 263.1 | — |
| SECONDARY Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Equal to or Above Cut-off Values |
110; 121; 110; 113; 110; 113 | — |
| SECONDARY Anti-HBs Antibody Concentrations |
211.1; 189.2; 154.5; 218.9; 130.8; 128.4 | — |
| SECONDARY Number of Subjects With Serious Adverse Events (SAEs) |
0; 0; 0; 0; 0; 0 | — |
Summary
This protocol posting deals with objectives & outcome measures of an extension phase when subjects are aged 3, 4 and 6 years of age. The objectives & outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00334334). The objectives & outcome measures of the booster phase are presented in a separate protocol posting (NCT number = NCT00463437).
The purpose of this study is to evaluate the persistence of pneumococcal, meningococcal serogroup C, Hib and Hepatits B antibodies after booster vaccination, when the subjects are aged 3, 4 and 6 years. No vaccine will be administered during this persistence phase of the study.
Eligibility Criteria
Inclusion Criteria
- Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
- A male or female between, and including, 36 and 40 months of age at the time of Visit 1; between, and including, 48 and 52 months of age at the time of Visit 2; and between, and including, 72 and 76 months of age at the time of Visit 3.
- Written informed consent obtained from the parent or guardian of the subject.
- Healthy subjects as established by medical history and clinical examination before entering into the study.
- Subjects who previously participated in the primary and booster studies, who received a full vaccination course with the vaccines corresponding to their group during the primary and booster studies and who were part, in the booster study, of the blood sampling subset.
Exclusion Criteria
- Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the first blood sampling.
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
- Administration of any additional meningococcal serogroup C, Hib, hepatitis B and pneumococcal vaccine since the end of the booster study
- History of meningococcal serogroup C, Haemophilus influenzae type b, hepatitis B and invasive pneumococcal diseases since the end of booster study.
- Any confirmed or suspected immunosuppressive or immunodeficient condition since the end of booster study, based on medical history and physical examination (no laboratory testing required).
- Administration of immunoglobulins and/or any blood products within the three months preceding the first blood sampling.
Data sourced from ClinicalTrials.gov (NCT00891176). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.